Teriparatide, a recombinant human parathyroid hormone (PTH) analog, is a synthetic peptide corresponding to the active 1-34 fragment of endogenous parathyroid hormone.
CAS registry number is 52232-67-4. Comprising 34 amino acids, teriparatide has a molecular weight of approximately 4,117.8 daltons and is produced using recombinant DNA technology.
*The following content is generated by AI and is for reference only.
Teriparatide Raw, chemically known as recombinant human parathyroid hormone (1-34), is a potent anabolic agent utilized primarily in the treatment of severe osteoporosis. Its molecular formula is C176H280N50O51S2, with a molecular weight of approximately 4,117 Daltons. The substance corresponds to CAS number 83919-87-3, which uniquely identifies this specific peptide sequence in chemical databases. Structurally, it represents the first 34 amino acids of the native 84-amino acid human parathyroid hormone, retaining full biological activity while lacking the carboxyl-terminal region responsible for catabolic effects when administered continuously.
The primary clinical application of Teriparatide Raw involves stimulating new bone formation in postmenopausal women and men at high risk of fracture who have failed or cannot tolerate other osteoporosis therapies. Unlike antiresorptive agents that merely slow bone loss, Teriparatide acts by intermittently activating the parathyroid hormone receptor on osteoblasts, thereby increasing bone mineral density and improving microarchitecture. This unique mechanism makes it particularly effective for patients with vertebral and non-vertebral fractures. In pharmaceutical manufacturing, the raw material serves as the critical starting point for synthesizing injectable formulations, requiring stringent purification and quality control to ensure sterility and potency.
Beyond its therapeutic role, Teriparatide Raw is extensively used in research settings to study bone metabolism, osteoblast differentiation, and signaling pathways related to calcium homeostasis. It is also a valuable tool in developing novel drug delivery systems and understanding the pathophysiology of metabolic bone diseases. Safety profiles indicate potential risks such as hypercalcemia and orthostatic hypotension, necessitating careful patient monitoring during treatment. As a biosynthetic peptide produced via recombinant DNA technology in E. coli, it offers high purity and consistency compared to earlier extraction methods. The global demand for this compound continues to rise due to the aging population and increasing prevalence of osteoporosis, solidifying its status as a cornerstone therapy in modern endocrinology and orthopedics.